Mersana Therapeutics Announces Partial Clinical Hold for XMT-1522 Clinical Trial
July 19, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc.(NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018
June 04, 2018 09:01 ET
|
Mersana Therapeutics, Inc.
Favorable Tolerability Profile and Early Signs of Efficacy Demonstrated First Disclosure of Clinical Data from Novel Dolaflexin Platform Mersana To Host Conference Call and Webcast Including...
Mersana Therapeutics to Present at the Jefferies Global Healthcare Conference
May 31, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual Meeting
May 22, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces First Quarter 2018 Financial Results and Provides Business Updates
May 14, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
Phase 1 Dose Escalation Trials Progressing for Lead Programs XMT-1522 and XMT-1536 Presented Data of Dolaflexin® Platform Unique DolaLock Technology and XMT-1522 Synergy with a Checkpoint Inhibitor...
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2018 Financial Results and Business Updates
May 07, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
May 01, 2018 16:01 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018
April 17, 2018 13:01 ET
|
Mersana Therapeutics, Inc.
Detailed Characterization of Unique DolaLock Technology Enhancements to Drug Efficacy and Tolerability XMT-1522 Demonstrates Synergy in Combination with a Checkpoint Inhibitor CAMBRIDGE, Mass.,...
Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018
April 09, 2018 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
March 28, 2018 07:30 ET
|
Mersana Therapeutics, Inc.
Enrollment on Track for Phase 1 Trial of XMT-1522 Patients with Advanced Tumors Expressing HER2 Progressing Phase 1 Trial of XMT-1536, First-in-Class Dolaflexin® Antibody Drug Conjugate Targeting...